Search hospitals > New Jersey > New Brunswick
Rutgers Cancer Institute of New Jersey
Claim this profileNew Brunswick, New Jersey 08901
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Solid Tumors
1005 reported clinical trials
65 medical researchers
Summary
Rutgers Cancer Institute of New Jersey is a medical facility located in New Brunswick, New Jersey. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Prostate Cancer, Solid Tumors and other specialties. Rutgers Cancer Institute of New Jersey is involved with conducting 1,005 clinical trials across 734 conditions. There are 65 research doctors associated with this hospital, such as Sanjay Goel, Janice M. Mehnert, Howard S. Hochster, and Eugenia Girda, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Sanjay GoelMontefiore Medical Center5 years of reported clinical research
Expert in Solid Tumors
Studies Cancer
21 reported clinical trials
30 drugs studied
Janice M. MehnertLaura and Isaac Perlmutter Cancer Center at NYU Langone5 years of reported clinical research
Expert in Melanoma
Studies Cancer
18 reported clinical trials
26 drugs studied
Howard S. HochsterRutgers Cancer Institute of New Jersey6 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
37 drugs studied
Eugenia Girda, MDRutgers Cancer Institute of New Jersey5 years of reported clinical research
Studies Ovarian Cancer
Studies Cancer
16 reported clinical trials
31 drugs studied
Clinical Trials running at Rutgers Cancer Institute of New Jersey
Breast Cancer
Lung Cancer
Prostate Cancer
Ovarian Cancer
Breast cancer
Testicular cancer
Multiple Myeloma
Neuroblastoma
Pancreatic Cancer
Kidney Cancer
Elacestrant
for Breast Cancer
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Recruiting2 awards Phase 33 criteria
PF-07220060 + Letrozole
for Breast Cancer
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Recruiting2 awards Phase 34 criteria
RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant
for Breast Cancer
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Rutgers Cancer Institute of New Jersey?
Rutgers Cancer Institute of New Jersey is a medical facility located in New Brunswick, New Jersey. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Prostate Cancer, Solid Tumors and other specialties. Rutgers Cancer Institute of New Jersey is involved with conducting 1,005 clinical trials across 734 conditions. There are 65 research doctors associated with this hospital, such as Sanjay Goel, Janice M. Mehnert, Howard S. Hochster, and Eugenia Girda, MD.
Where is Rutgers Cancer Institute of New Jersey located?
**Rutgers Cancer Institute of New Jersey**
- **Address:** 195 Little Albany Street, New Brunswick, NJ.
- **Transportation:** Accessible by car, bus (810, 811, 814, 815, 818), and train (New Jersey Transit/Northeast Corridor Line).
Who should I call to ask about financial aid or insurance network?
**Financial Assistance and Support at Rutgers Cancer Institute of New Jersey:**
- For financial assistance, contact the New Patient Access Center at 732-235-2465.
- For insurance inquiries, visit the Rutgers Cancer Institute of New Jersey's website or call 732-235-2465.
- Additional resources include CancerCare for financial aid related to cancer treatment costs and the Cancer Support Community for support, education, and hope.
What insurance does Rutgers Cancer Institute of New Jersey accept?
The Rutgers Cancer Institute of New Jersey accepts a wide range of insurance plans, including CHN PPO, Cigna, First MCO/ActiveCare, Group Health Incorporated (GHI), Health Care Payers Coalition, Horizon BCBS, and many others. Patients are encouraged to contact their insurance company to verify coverage details and financial responsibilities. Financial counselors at the Institute are available to assist with maximizing benefits; for consultations, contact 732-235-8067.
What awards or recognition has Rutgers Cancer Institute of New Jersey received?
Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, underscores its commitment to research, treatment, prevention, and care. It has received a transformative investment of $750 million for the construction of New Jersey's first free-standing cancer hospital, the Jack and Sheryl Morris Cancer Center in New Brunswick. This funding and recognition for research and care solidify its leading position in cancer treatment and research.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.